189 related articles for article (PubMed ID: 28659181)
21. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
22. ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Ryu H; Song IC; Choi YS; Yun HJ; Jo DY; Kim JM; Ko YB; Lee HJ
Medicine (Baltimore); 2017 Dec; 96(51):e9402. PubMed ID: 29390553
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Benner SE; Lippman SM; Huber MH; Hong WK
Semin Oncol; 1995 Oct; 22(5 Suppl 12):22-5. PubMed ID: 7481857
[TBL] [Abstract][Full Text] [Related]
24. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
Hwang IG; Jang JS; Do JH; Kang JH; Lee GW; Oh SY; Kwon HC; Jun HJ; Lim HY; Lee S; Chi KC; Lee SJ
Cancer Chemother Pharmacol; 2011 Oct; 68(4):935-44. PubMed ID: 21298384
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.
Zanetta G; Fei F; Parma G; Balestrino M; Lissoni A; Gabriele A; Mangioni C
Ann Oncol; 1999 Oct; 10(10):1171-4. PubMed ID: 10586332
[TBL] [Abstract][Full Text] [Related]
26. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.
Park Y; Kim DS; Park KH; Baek SK; Kwon SY; Shin SW; Jung KY; Kim CY; Kim YH; Lee NJ; Kim JS; Kim IS
Onkologie; 2012; 35(11):673-82. PubMed ID: 23147544
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
28. Combined chemotherapy using cisplatin, ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma.
Tay SK; Lai FM; Soh LT; Ho TH; Ang PT; Au E
Aust N Z J Obstet Gynaecol; 1992 Aug; 32(3):263-6. PubMed ID: 1280100
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
30. Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
Murata S; Onozawa S; Sugihara F; Sakamoto A; Ueda T; Yamaguchi H; Yasui D; Mine T; Kumita S
Ann Surg Oncol; 2015 Nov; 22(12):3981-9. PubMed ID: 25758191
[TBL] [Abstract][Full Text] [Related]
31. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
32. Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Khoury-Collado F; Bowes RJ; Jhamb N; Aghajanian C; Abu-Rustum NR
Gynecol Oncol; 2007 Jun; 105(3):823-5. PubMed ID: 17363045
[TBL] [Abstract][Full Text] [Related]
33. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
Downs LS; Chura JC; Argenta PA; Judson PL; Ghebre R; Geller MA; Carson LF
Gynecol Oncol; 2011 Feb; 120(2):265-9. PubMed ID: 21145100
[TBL] [Abstract][Full Text] [Related]
34. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
35. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy for recurrent and metastatic cervical cancer with standard-dose methotrexate-leucovorin, bleomycin and cis-platinum.
Vogl SE; Seltzer V; Camacho F; Davis TE
J Reprod Med; 1986 May; 31(5):327-9. PubMed ID: 2427717
[No Abstract] [Full Text] [Related]
38. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Moore KN; Herzog TJ; Lewin S; Giuntoli RL; Armstrong DK; Rocconi RP; Spannuth WA; Gold MA
Gynecol Oncol; 2007 May; 105(2):299-303. PubMed ID: 17303230
[TBL] [Abstract][Full Text] [Related]
39. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
Hasegawa K; Kato R; Torii Y; Ichikawa R; Oe S; Udagawa Y
Int J Gynecol Cancer; 2011 Nov; 21(8):1479-85. PubMed ID: 21720251
[TBL] [Abstract][Full Text] [Related]
40. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
